Possible links between esophageal cancer and osteoporosis drugs

The FDA is investigating whether certain drugs used to treat osteoporosis are associated with an increased risk of esophageal cancer. At this time, the FDA has not found conclusive evidence linking the medications, called oral bisphosphonates, with esophageal cancer. However, the agency is continuing to evaluate all data available and will alert the public if a more conclusive link is discovered.

Research so far reveals mixed findings about the ties between oral bisphosphonates and esophageal cancer. Esophageal injuries have been reported in patients who took these drugs, particularly those patients who did not follow the exact instructions on their prescriptions.

At this point, the FDA recommends that patients work with their doctors to weigh the risks and benefits of taking oral bisphosphonates. If complications develop, patients should see their doctors immediately. The FDA also stresses the importance of properly following prescription instructions at all times.

Patients who take oral bisphosphonates are encouraged to report any unexpected adverse effects they experience in relation to use of these drugs.